Neutrophil biology and the next generation of myeloid growth factors

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 7, Issue 1, 2009, Pages 92-98

  Dale, David C ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Bio similars; Follow on proteins; Granulocyte colony stimulating factor; Myeloid growth factors; Neutropenia; Neutrophils; Pegylated granulocyte colony stimulating factor

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL; MYELOID GROWTH FACTOR; PLERIXAFOR; POLOXAMER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; BIOLOGICAL ACTIVITY; CHEMICAL MODIFICATION; CLINICAL TRIAL; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TREATMENT FAILURE; HUMAN; LEUKOCYTE FUNCTION; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION;

EID: 58149337137     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2009.0008     Document Type: Article

References (58)

1. Dale DC. Nonmalignant disorders of leukocytes. In: Dale DC, Federman DD, eds. ACP Medicine 2006. New York: WebMD, Inc.; 2006:1030-1037.
2. Dale DC, Boxer LA, Liles WC. The phagocytes: neutrophils and monocytes. Blood 2008;112:935-945.
3. Cartwright GE, Athens JW, Wintrobe MM. The kinetics of granulopoiesis in normal man. Blood 1964;24:780-803.
4. Dancey JT, Deubelbeiss KA, Harker LA, Finch CA. Neutrophil kinetics in man. J Clin Invest 1976;58:705-715
5. Metcalf D. Hematopoietic cytokines. Blood 2008;111:485-491.
6. Chatta GS, Price TH, Allen RC, Dale DC. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994;84:2923-2929.
7. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996;88:335-340.
8. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008;111:1767-1772.
9. Hübel K, Dale DC, Liles WC. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis 2002;185:1490-1501.
10. Christopher MJ, Link DC. Regulation of neutrophil homeostasis. Curr Opin Hematol 2007;14:3-8.
11. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 1992;327:99-106.
12. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-170.
13. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80:1430-1436.
14. Applebaum FR. The clinical use of hematopoietic growth factors. Semin Hematol 1989;26:7-14.
15. Dale DC, Bonilla MA, Davis MW, et al. A tandomized controlled phase III trial of recombinant human G-CSF for treatment of severe chronic neutropenia. Blood 1993;181:2496-2502.
16. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187-3205.
17. Lyman GH, Kleiner JM. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. J Natl Compr Canc Netw 2007;5:217-228.
18. Gaberc-Porekar V, Zore I, Podobnik B, Menart V. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Devel 2008;11:242-250.
19. Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003;23:3S-8S.
20. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-731.
21. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
22. Kubista E, Glaspy J, Holmes FA, et al. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 2003;3:391-398.
23. Medical News Today. Maxygen announces positive progress in phase IIa clinical trial of novel PEG-G-CSF Available at: http://www.medicalnewstoday.com/articles/93201.php. Accessed July 15, 2008.
24. Neose. Presentation of Glycopeg-G-CSF phase I data (conference call and webcast (November 7, 2007). Available at: http://www.neose.com/ pages.hrmlMENUS/techMENU/htm. Accessed July 16, 2008.
25. DeFrees S, Wang ZG, Xing R, et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 2006;16:833-843.
26. Doherty DH, Rosendahl MS, Smith DJ, et al. Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor. Bioconjug Chem 2005;16:1291-1298.
27. Robinson SN, Chavez JM, Blonder JM, et al. Hematopoietic progenitor cell mobilization in mice by sustained delivery of granulocyte colony-stimulating factor. J Interferon Cytokine Res 2005;25: 490-500.
28. Blonder JM, Robinson SN, Chavez JM, et al. G-CSF for formulated in a pluronic-based matrix shows extended pharmacokinetics and enhanced hematopoietic activity. Blood 2001;98:1251.
29. Cox GN, Smith DJ, Carlson SJ, et al. Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein. Exp Hermatol 2004;32:441-449.
30. Halpern W, Riccobene TA, Agostini H, et al. Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm Res 2002;19: 1720-1729.
31. Erben U, Thiel E, Notter M. Differential effects of a stem cell factor-immunoglobulin fusion protein on malignant and normal hematopoietic cells. Cancer Res 1999;59:2924-2930.
32. Chadwick DE, Williams DP, Niho Y, et al. Cytotoxicity of a recombinant diphtheria toxin-granulocyte colony-stimulating factor fusion protein on human leukemic blast cells. Leuk Lymphoma 1993;11:249-262.
33. Asano Y, Yokoyama T, Shibata S, et al. Effect of the chimeric soluble granulocyte colony-stimulating factor receptor on the proliferation of leukemic blast cells from patients with acute myeloblastic leukemia. Cancer Res 1997;57:3395-3397.
34. MacVittie TJ, Farese AM, Smith WG, et al. Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression. Blood 2000;95:837-845.
35. Williams DE, Park LS. Hematopoietic effects of a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein. Cancer 1991;67(10 Suppl):2705-2707.
36. Vadhan-Raj S, Broxmeyer HE, Andreeff M, et al. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood 1995;86:2098-2105.
37. Lee AY, Chung HK, Bae EK, et al. A recombinant human G-CSF/GM-CSF fusion protein from E. coli showing colony stimulating activity on human bone marrow cells. Biotechnol Lett 2003;25:205-211.
38. Miller SG. Discovery of cytokine mimics using cell-based systems. Drug Discov Today 2000:5(Suppl 1):77-83.
39. Tian S, Lamb P, King AG, et al. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor. Science 1998;281:257-259.
40. Barinaga M. Small molecular fills hormone's shoes. Science 1998; 281:149-150.
41. Shibata K, Maruyama-Takahashi K, Yamasaki M, Hirayama N. G-CSF receptor-binding cyclic peptides designed with artificial amino-acid linkers. Biochem Biophys Res Commun 2006;341:483-488.
42. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London: European Medicines Agency (EMEA);2006.
43. Draft guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs). Ottowa: Health Canada; 2008.
44. Dudzinski DM, Kesselheim AS. Scientific and legal viability of follow-on protein drugs. N Engl J Med 2008;358:843-849.
45. Pollock C, Johnson DW, Hörl WH, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008;3:1939.
46. Committee for Medicinal Products for Human Use (CHMP). Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor. London: European Medicines Agency (EMEA);2006.
47. Pavlovic M, Girardin E, Kapetanovic L, et al. Similar biological medicinal products containing recombinant human growth hormone: European regulation. Horm Res 2008;69:14-21.
48. Reuters. Teva's developed G-CSF is the first biosimilar to receive positive opinion from European Medicines Agency (EMEA). Available at: http://www.reuters.com/article/pressRelease/ idUS196489+21-Feb-2008+BW20080221. Accessed July 17, 2008.
49. Woodcock J, Griffin J, Behrman R, et al. The FDA's assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov 2007;6:437-442.
50. Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/ progenitor cell mobilization. Blood 2004;103:1580-1585.
51. Winkler IG, Lévesque JP. Mechanisms of hematopoietic Stem cell mobilization: when innate immunity assails the cells that make blood and bone. Exp Hematol 2006;34:996-1009.
52. Semerad CL, Christopher MJ, Liu F, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005;106:3020-3027.
53. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005;201:1307-1318.
54. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005;45:295-300.
55. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41:331-338.
56. Hübel K, Carter RA, Liles WC, et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 2002;42:1414-1421.
57. Ofran Y, Avivi I, Oliven A, et al. Granulocyte transfusions for neutropenic patients with life-threatening infections: a single centre experience in 47 patients, who received 348 granulocyte transfusions. Vox Sang 2007;93:363-369.
58. Boiron JM, Dazey B, Cailliot C, et al. Large-scale expansion and transplantation of CD34+ hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacity. Transfusion 2006;46:1934-1942.